Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **hemagglutinin globular head domain** is a structurally distinct region of the influenza virus hemagglutinin (HA) protein, found at the tip of each HA monomer that forms the viral spike. It is composed mainly of the N-terminal HA1 subunit and is responsible for binding to sialic acid-containing receptors on the surface of host cells, which is crucial for viral attachment and entry. The head domain is the primary target of neutralizing antibodies and is a major focus of seasonal and pandemic influenza vaccine strategies. However, it is also subject to frequent antigenic drift, enabling the virus to evade immunity developed against previous strains. Its functional and immunogenic importance make the HA head domain a central target for both vaccine design and therapeutic antibodies in influenza infection[1][2][4][6][7][8].
Neutralizing antibodies prevent viral entry by blocking sialic acid binding Inhibitors and antibodies may prevent attachment to host cell or accelerate clearance by immune system
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza hemagglutinin globular head domain (HA head domain).